JAK
Gli inibitori della Janus chinasi (JAK) sono composti che prendono di mira la via di segnalazione JAK-STAT, coinvolta nella crescita cellulare, nella risposta immunitaria e nell'angiogenesi. Inibendo JAK, questi composti possono ridurre la segnalazione che porta alla formazione di nuovi vasi sanguigni nei tumori, inibendo così la crescita tumorale. Gli inibitori di JAK sono importanti nel trattamento del cancro e delle malattie infiammatorie. Presso CymitQuimica, offriamo una vasta gamma di inibitori di JAK di alta qualità per supportare la tua ricerca in oncologia, immunologia e angiogenesi.
Trovati 246 prodotti di "JAK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
WP1066
CAS:WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3.Formula:C17H14BrN3OPurezza:98.92% - 99.73%Colore e forma:SolidPeso molecolare:356.22AZ960
CAS:AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).Formula:C18H16F2N6Purezza:96.02% - 99.88%Colore e forma:SolidPeso molecolare:354.36JANEX-1
CAS:JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.Formula:C16H15N3O3Purezza:98% - 99.81%Colore e forma:SolidPeso molecolare:297.31WHI-P97
CAS:WHI-P97 is a rationally designed potent inhibitor of JAK-3.Formula:C16H13Br2N3O3Purezza:99.93%Colore e forma:SolidPeso molecolare:455.1Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Formula:C18H16FN3OPurezza:97.1% - 98.74%Colore e forma:SolidPeso molecolare:309.34Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formula:C16H17N7O2SPurezza:99% - >99.99%Colore e forma:SolidPeso molecolare:371.42GDC-0214
CAS:GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).Formula:C28H28ClF2N9O3Purezza:99.75%Colore e forma:SolidPeso molecolare:612.03AG490
CAS:AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.Formula:C17H14N2O3Purezza:98.6% - 99.85%Colore e forma:Yellow SolidPeso molecolare:294.3ZM39923 hydrochloride
CAS:ZM39923 hydrochloride (JAK3 Inhibitor IV) is an JAK1/3 inhibitor, almost no activity to JAK2 and modestly potent to EGFR; also is sensitive to transglutaminase.Formula:C23H25NO·HClPurezza:98.05%Colore e forma:SolidPeso molecolare:367.91Pacritinib hydrochloride
CAS:Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.Formula:C28H32N4O3·xClHColore e forma:SolidFLLL32
CAS:FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).Formula:C28H32O6Purezza:97% - 97.90%Colore e forma:SolidPeso molecolare:464.55(E/Z)-Zotiraciclib
CAS:(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.Formula:C23H24N4OPurezza:97.75% - 99.92%Colore e forma:SolidPeso molecolare:372.46RO8191
CAS:RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.Formula:C14H5F6N5OPurezza:98% - 98.85%Colore e forma:SolidPeso molecolare:373.21G5-7
CAS:G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.Formula:C22H19F2NO3Purezza:97.3%Colore e forma:SolidPeso molecolare:383.39Decernotinib
CAS:Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.Formula:C18H19F3N6OPurezza:99.28% - >99.99%Colore e forma:SolidPeso molecolare:392.38Oclacitinib maleate
CAS:Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.Formula:C15H23N5O2S·C4H4O4Purezza:99.17% - 99.92%Colore e forma:SolidPeso molecolare:453.51SAR-20347
CAS:SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).Formula:C21H18ClFN4O4Purezza:98.99% - 99.77%Colore e forma:SolidPeso molecolare:444.84JAK3-IN-6
CAS:JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nMFormula:C19H18N4O3Purezza:99.94% - 99.94%Colore e forma:SolidPeso molecolare:350.37Tofacitinib Citrate
CAS:Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).Formula:C22H28N6O8Purezza:99.19% - 99.75%Colore e forma:SolidPeso molecolare:504.49SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Formula:C18H22N8O2SPurezza:99.11%Colore e forma:SolidPeso molecolare:414.48Brevilin A
CAS:Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.Formula:C20H26O5Purezza:99.97% - >99.99%Colore e forma:SolidPeso molecolare:346.42Gandotinib
CAS:LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).Formula:C23H25ClFN7OPurezza:99.33% - 99.86%Colore e forma:SolidPeso molecolare:469.94Oclacitinib
CAS:Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000Formula:C15H23N5O2SPurezza:98% - 98.45%Colore e forma:White To Off-White SolidPeso molecolare:337.44Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Formula:C17H21N6O4PPurezza:98% - >99.99%Colore e forma:SolidPeso molecolare:404.36AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formula:C29H28F3N5O2Purezza:98%Colore e forma:SolidPeso molecolare:535.56Delgocitinib EtOH
CAS:Delgocitinib (LEO-124249/JTE052) is a selective JAK inhibitor used for reducing skin inflammation and treating chronic dermatitis.Formula:C18H24N6O2Colore e forma:SolidPeso molecolare:356.43SC99
CAS:SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.Formula:C15H8Cl2FN3OPurezza:99.56%Colore e forma:SolidPeso molecolare:336.15RGB-286638 free base
CAS:RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.Formula:C29H35N7O4Purezza:98% - 99.91%Colore e forma:SolidPeso molecolare:545.63Cerdulatinib hydrochloride
CAS:Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.Formula:C20H28ClN7O3SPurezza:99.85%Colore e forma:SolidPeso molecolare:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Formula:C17H19N5O2SPurezza:99.93%Colore e forma:SolidPeso molecolare:357.43Osunprotafib
CAS:Osunprotafib (ABBV-CLS-484) is a potent, orally bioavailable PTP1B/PTPN2 inhibitor in clinical trials for solid tumors.Cost-effective and quality-assured.Formula:C17H24FN3O4SPurezza:97.11% - 99.91%Colore e forma:SolidPeso molecolare:385.45NVP-BSK805
CAS:NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.Formula:C27H28F2N6OPurezza:98%Colore e forma:SolidPeso molecolare:490.55ZM39923
CAS:ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).Formula:C23H25NOPurezza:98%Colore e forma:SolidPeso molecolare:331.45(3S,4S)-Tofacitinib
CAS:(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.Formula:C16H20N6OPurezza:98%Colore e forma:SolidPeso molecolare:312.37SD-1029
CAS:SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.Formula:C25H32Br2Cl2N2O3Colore e forma:SolidPeso molecolare:639.25JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formula:C23H22FN5O4SPurezza:99.75%Colore e forma:SolidPeso molecolare:483.52JAK-IN-20
CAS:JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.Formula:C28H30FN7O2Colore e forma:SolidPeso molecolare:515.58JAK-2/3-IN-2
CAS:JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).Formula:C19H19ClN2OSColore e forma:SolidPeso molecolare:358.89Peficitinib hydrochloride
CAS:Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).Formula:C18H23ClN4O2Colore e forma:SolidPeso molecolare:362.86TK4b
CAS:TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).Formula:C21H22N2O2Colore e forma:SolidPeso molecolare:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Formula:C19H19N3O4SColore e forma:SolidPeso molecolare:385.44JAK-IN-14
CAS:JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.Formula:C19H15FN4OPurezza:98.27%Colore e forma:SolidPeso molecolare:334.35TyK2-IN-2
CAS:TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).Formula:C16H18N6OPurezza:98%Colore e forma:SolidPeso molecolare:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Formula:C27H28F2N6O3Colore e forma:SolidPeso molecolare:522.55JAK3-IN-12
CAS:JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.Formula:C19H19N5O4SColore e forma:SolidPeso molecolare:413.45Tyk2-IN-5
CAS:Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).Formula:C21H19FN8O2Purezza:98%Colore e forma:SolidPeso molecolare:434.43EP009
CAS:EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.Formula:C14H24O2Colore e forma:SolidPeso molecolare:224.34Tyk2-IN-7
CAS:Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).Formula:C18H15D3N6O3SPurezza:98%Colore e forma:SolidPeso molecolare:401.46MS-1020
CAS:MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.Formula:C21H18N2O3Purezza:98%Colore e forma:SolidPeso molecolare:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.Formula:C6H6Br6Purezza:98%Colore e forma:SolidPeso molecolare:557.54OICR-0547
CAS:OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.Formula:C28H29F3N4O4Purezza:98%Colore e forma:SolidPeso molecolare:542.55INCB16562
CAS:INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.Formula:C19H11Cl2N5Colore e forma:SolidPeso molecolare:380.23JAK3-IN-9
CAS:JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.Formula:C17H23N5O4SColore e forma:SolidPeso molecolare:393.46TUL01101
CAS:TUL01101, a selective oral JAK1 inhibitor (IC50: 3 nM), also targets JAK2, JAK3, TYK2; for rheumatoid arthritis research.Formula:C22H25F2N5O2Colore e forma:SolidPeso molecolare:429.46CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Colore e forma:SolidPeso molecolare:303.36GDC-4379
CAS:GDC-4379 is a JAK1 inhibitor that can be used to study asthma.Formula:C21H18ClF2N7O3Colore e forma:SolidPeso molecolare:489.86Peficitinib hydrobromide
CAS:Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.Formula:C18H23BrN4O2Colore e forma:SolidPeso molecolare:407.312Povorcitinib
CAS:Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneous lupus erythematosus (CLE) and Lichen planus (LP).Formula:C23H22F5N7OColore e forma:SolidPeso molecolare:507.469(2R,5S)-Ritlecitinib
CAS:(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective inhibitor of JAK3 with IC 50 of 144.8 nM[1].Formula:C15H19N5OColore e forma:SolidPeso molecolare:285.34TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColore e forma:SolidPeso molecolare:383.42Thi-DPPY
CAS:Thi-DPPY: Potent JAK3/BTK inhibitor (IC50: 1.38/62.4 nM), anti-proliferative, anti-inflammatory, potential in IPF research.Formula:C28H28ClN5O4SColore e forma:SolidPeso molecolare:566.07PF-00956980
CAS:PF-00956980: reversible JAK inhibitor, IC50: JAK1 (2.2μM), JAK2 (23.1μM), JAK3 (59.9μM), for lung/skin inflammation research.Formula:C18H26N6OColore e forma:SolidPeso molecolare:342.44SYK/JAK-IN-1
CAS:SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2.Formula:C24H26N8O3Colore e forma:SolidPeso molecolare:474.52JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Formula:C26H30ClN7O2Colore e forma:SolidPeso molecolare:508.02AC430
CAS:AC430, a specific JAK2 inhibitor for cancer and autoimmune therapy, excels in preclinical trials with low doses. Developed by Ambit.Formula:C19H16FN5OColore e forma:SolidPeso molecolare:349.36JAK-IN-10
CAS:<p>JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.</p>Formula:C20H18FN5O3SPurezza:99.53%Colore e forma:SolidPeso molecolare:427.45JAK-IN-28
CAS:JAK-IN-28 (Compound 111) is a Janus kinase (JAK) inhibitor potentially applicable in the research of cancer and inflammatory diseases [1].Formula:C20H18ClN7OPurezza:98%Colore e forma:SolidPeso molecolare:407.86JAK-IN-30
CAS:JAK-IN-30 (compound 31) is a water-soluble inhibitor of Janus kinases (JAKs), demonstrating inhibitory potency with half-maximal inhibitory concentration (IC50Formula:C19H26N8SPurezza:98%Colore e forma:SolidPeso molecolare:398.53JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purezza:98%Colore e forma:SolidPeso molecolare:521.59JAK3/BTK-IN-2
CAS:<p>JAK3/ BTk-in-2 is a potent JAK3/BTK inhibitor.</p>Formula:C25H32N8O2Purezza:99.64% - 99.87%Colore e forma:SolidPeso molecolare:476.57Lorpucitinib
CAS:Lorpucitinib (JNJ-64251330) is a JAK kinase inhibitor used in the study of inflammatory and gastrointestinal diseases.Formula:C22H28N6O2Purezza:99.72%Colore e forma:SolidPeso molecolare:408.5JAK3i
CAS:<p>JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.</p>Formula:C18H15FN4O3Purezza:98.61% - 99.81%Colore e forma:SolidPeso molecolare:354.34Jaspamycin
CAS:Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.Formula:C12H12N4O5Colore e forma:SolidPeso molecolare:292.25JAK3/BTK-IN-1
CAS:<p>JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important</p>Formula:C25H28N8OPurezza:97.89%Colore e forma:SolidPeso molecolare:456.54STS-E412
CAS:STS-E412 is a tissue-protective and selective EPOR/CD131 receptor activator for the study of neurological disorders.Formula:C15H15ClN4O2Purezza:99.01%Colore e forma:SolidPeso molecolare:318.76Izencitinib
CAS:<p>Izencitinib (JNJ-8398) is a JAK inhibitor with potential anti-inflammatory activity for the study of ulcerative colitis and Crohn;s disease.</p>Formula:C22H26N8Purezza:99.82%Colore e forma:SolidPeso molecolare:402.50JAK-STAT-IN-1
CAS:JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.Formula:C21H21N5O2Purezza:99.59%Colore e forma:SolidPeso molecolare:375.42JAK1-IN-8
CAS:<p>JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).</p>Formula:C22H23FN4O3SPurezza:98.4%Colore e forma:SolidPeso molecolare:442.51Butyzamide
CAS:<p>Butyzamide: oral Mpl activator, non-peptide, antagonizes TPO receptors, boosts hMpl, Ba/F3 cells, and enhances platelets in mice.</p>Formula:C29H32Cl2N2O5SPurezza:99.51% - 99.83%Colore e forma:SoildPeso molecolare:591.55JAK-IN-17
"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."Formula:C33H38F2N6O8Colore e forma:SolidPeso molecolare:684.69Ginsenoside Rk1
CAS:Ginsenoside Rk1 is a component created by processing the ginseng plant at high temperatures.Formula:C42H70O12Purezza:98.46% - 99.13%Colore e forma:SolidPeso molecolare:767.00Tyk2-IN-9
CAS:Tyk2-IN-9: selective Tyk-2 inhibitor, IC50 of 0.076 nM (TYK2-JH2), 1.8 nM (JAK1-JH2), for inflammation/autoimmune research.Formula:C20H17N9Purezza:98%Colore e forma:SolidPeso molecolare:383.41TCJL37
CAS:TCJL37: potent, selective TYK2 inhibitor (K i 1.6 nM), oral, for IBD research.Formula:C17H11ClF2N4O2Colore e forma:SolidPeso molecolare:376.74JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Colore e forma:SolidPeso molecolare:367.44Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purezza:98%Colore e forma:SolidPeso molecolare:602.521JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurezza:98%Colore e forma:SolidPeso molecolare:466.341Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Colore e forma:SolidPeso molecolare:527.66FM-479
CAS:<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>Formula:C25H26N6O2Purezza:98%Colore e forma:SolidPeso molecolare:442.523TCS 21311
CAS:<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formula:C27H25F3N4O4Purezza:99.39% - ≥98%Colore e forma:SolidPeso molecolare:526.51Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purezza:99.85%Colore e forma:SolidPeso molecolare:355.39JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:380.44Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Colore e forma:SolidPeso molecolare:416.43JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Formula:C23H27N5O4SPurezza:98%Colore e forma:SolidPeso molecolare:469.56Brepocitinib
CAS:Brepocitinib (PF-06700841) is a potent dual JAK1/TYK2 inhibitor (IC50s: 17 nM/23 nM). Brepocitinib also inhibits JAK2/3 (IC50s: 77 nM/6.49 μM).Formula:C18H21F2N7OPurezza:99.82%Colore e forma:SolidPeso molecolare:389.4JAK-IN-26
CAS:JAK-IN-26 (compound 2) is an orally active inhibitor of the Janus kinase (JAK) enzyme with favorable pharmacokinetic properties, exhibiting potency inFormula:C22H24N6O3Purezza:98%Colore e forma:SolidPeso molecolare:420.46JAK-IN-31
CAS:JAK-IN-31 (Example 75), a JAK inhibitor, demonstrates IC50 values of ≤0.01 µM for JAK1, ≤0.01 µM for JAK2, 0.01-0.1 µM for JAK3, and ≤0.01 µM for Tyk2,Formula:C21H19N7O2S2Purezza:98%Colore e forma:SolidPeso molecolare:465.55QL-1200186
CAS:QL-1200186 is an orally active, selective TYK2 inhibitor that, upon dose-dependent oral administration, suppresses interferon-γ (IFNγ) production followingFormula:C26H27N7O3Purezza:98%Colore e forma:SolidPeso molecolare:485.54JAK kinase-IN-1
CAS:<p>JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32</p>Formula:C17H19F2N7OSPurezza:98%Colore e forma:SolidPeso molecolare:407.44JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formula:C19H17N5O4Purezza:98%Colore e forma:SolidPeso molecolare:379.37ABBV-712
CAS:<p>ABBV-712 is a selective Tyrosine Kinase 2 (TYK2) inhibitor, demonstrating an IC50 value of 0.195 μM, and is implicated in the regulation of autoimmune diseases</p>Formula:C24H28N4O5Purezza:98%Colore e forma:SolidPeso molecolare:452.5
